Therapeutic potential of anti-HIV immunotoxins

Antiviral Research

Volumn 33, Issue 1, 1996, Pages 1-9

  Pincus, Seth H ^a  

^a MONTANA STATE UNIVERSITY   (United States)

Author keywords

AIDS; Anti HIV immunotoxins; HIV; Immunotoxin

Indexed keywords

CD4 ANTIGEN DERIVATIVE; IMMUNOTOXIN; INTERLEUKIN 2 RECEPTOR; VIRUS ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOTHERAPY; PRIORITY JOURNAL; REVIEW; VIRUS INFECTION;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0030272992     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(96)00995-3     Document Type: Article

References (39)

1. Allaway, G.P., Davis-Bruno, K.L., Beaudry, G.A. et al. (1995) Expression and characterization of CD4-IgG2, a novel heteroteramer that neutralizes primary HIV-1 isolates. AIDS Res. Hum. Retroviruses 11, 533-539.
2. Amlot, P.L., Stone, M.J., Cunningham, D. et al. (1993) A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 82, 2624-2633.
3. Ashorn, P., Moss, B., Weinstein, J.N. et al. (1990) Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors. Proc. Natl. Acad. Sci. USA 87, 8889-8893.
4. Ashorn, P., Englund, G., Martin, M.A., Moss, B. and Berger, E.A. (1991) Anti-HIV activity of CD4-Pseudomonas exotoxin on infected primary human lymphocytes and monocyte/macrophages. J. Infect. Dis. 163, 703-709.
5. Bell, K.D., Ramilo, O. and Vitetta, E.S. (1993) Combined use of an immunotoxin and cyclosporine to prevent both activated and quiescent peripheral blood T cells from producing type 1 human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 90, 1411-1415.
6. Borvak, J., Chou, C.-S., Bell, K., Van Dyke, G., Zola, H., Ramilio, O. and Vitetta, E.S. (1995) Expression of CD25 defines peripheral blood mononuclear cells with productive versus latent HIV infection. J. Immunol. 155, 3196-3204.
7. Chaudhary, V.K., Mizukami, T., Fuerst, T.R., FitzGerald, D.J., Moss, B., Pastan, I. and Berger, E.A. (1988) Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein. Nature 335, 369-372.
8. Chen, S.-Y., Zani, C., Khouri, Y. and Marasco, W.A. (1995) Design of a genetic immunotoxin to eliminate toxin immunogenicity. Gene Ther. 2, 116-123.
9. Collier, A.C., Coombs, R.W., Schoenfeld, D.A. et al. (1996) Treatment of HIV infection with Saquinavir, Zidovudine, and Zalcitabine. New Engl. J. Med. 334, 1011-1017.
10. Davey, R.T., Boenning, C.M., Herpin, B.R. et al. (1994) Recombinant soluble CD4-pseudomonas exotoxin, a novel immunotoxin, in the treatment of individuals infected with HIV. J. Inf. Dis. 170, 1180-1188.
11. Duensing, T.D., Fang, H., Dorward, D.W. and Pincus, S.H. (1995) Processing of the envelope glycoprotein gp160 in immunotoxin-resistant cell lines chronically infected with HIV-1. J. Virol. 69, 7122-7131.
12. Fang, H. and Pincus, S.H. (1995) Unique insertion sequence and pattern of CD4 expression in variants selected with immunotoxins from human immunodeficiency virus type 1-infected T cells. J. Virol. 69, 75-81.
13. Finberg, R.W., Wahl, S.M., Allen, J.B. et al. (1991) Selective elimination of HIV-1-infected cells with an interleukin-2 receptor-specific cytotoxin. Science 252, 1703-1705.
14. Frankel, A.E., Fitzgerald, D., Siegall, C. and Press, O.W. (1996) Advances in immunotoxin biology and therapy. Cancer Res. 56, 926-932.
15. Ives, D.V., Schaad, H., Hirschhorn, L. et al. (1994) Phase I/II evaluation of DAB-IL2 in HIV Infection. Abstracts ICAAC 34, 126.
16. Kaminski, M.S., Zasadny, K.R., Francis, I.R. et al. (1993) Radioimmunotherapy of B-cell lymphoma with 131-I anti-B1 (anti-CD20) antibody. N. Engl. J. Med. 329, 459-465.
17. Kennedy, P.E., Moss, B. and Berger, E.A. (1993) Primary HIV-1 refractory to neutralization by soluble CD4 are potently inhibited by CD4-Pseudomonas exotoxin. Virology 192, 375-379.
18. LeMaistre, C. F., Rosen, S., Frankel, A. et al. (1991) Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma. Blood 78, 1173-1182.
19. Muster, T., Steindl, F., Purtscher, M. et al. (1993) A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67, 6642-6647.
20. Pincus, S.H., Wehrly, K. and Chesebro, B. (1989) Treatment of HIV tissue culture infection with monoclonal antibody-ricin A chain conjugates. J. Immunol. 142, 3070-3075.
21. Pincus, S.H. and Wehrly, K. (1990) AZT demonstrates anti-HIV-1 activity in persistently infected cell lines: implications for combination chemotherapy and immunotherapy. J. Infect. Dis. 162, 1233-1238.
22. Pincus, S.H., Wehrly, K., Tschachler, E., Hayes, S.F., Buller, R.S. and Reitz, M. (1990) Variants selected by treatment of human immunodeficiency virus-infected cells with an immunotoxin. J. Exp. Med. 172, 745-757.
23. Pincus, S.H., Cole, R.L., Hersh, E.M., Lake, D., Masuho, Y., Durda, P.J. and McClure, J. (1991) In vitro efficacy of anti-HIV immunotoxins targeted by various antibodies to the envelope protein. J. Immunol. 146, 4315-4324.
24. Pincus, S.H. and McClure, J. (1993) Soluble CD4 enhances the efficacy of immunotoxins directed against gp41 of the human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 90, 332-336.
25. Pincus, S.H. (1994) Anti-HIV immunotoxins: gp41 rather than gp120 should be the target. Int. Antiviral News 2, 147-148.
26. Pincus, S.H., McClure, J. and Fang, H. (1994) Use of anti-HIV immunotoxins as probes of the biology of HIV-infected cells. Can. J. Infect. Dis. 5(suppl. A), 23A-27A.
27. Pincus, S.H. and Tolstikov, V.V. (1995) Anti-human immunodeficiency virus immunoconjugates. Adv. Pharmacol. 32, 205-242.
28. Pincus, S.H., Wehrly, K., Cole, R. et al. (1996) In vitro effects of anti-HIV immunotoxins directed against multiple epitopes on the HIV-1 envelope glycoprotein gp160. AIDS Res. Hum. Retro viruses, 12, 1041-1051.
29. Press, O.W., Eary, J.F., Appelbaum, F.R. et al. (1993) Radio-labeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med. 329, 1219-1224.
30. Ramachandran, R.V., Katzenstein, D.A., Wood, R., Batts, D.H. and Merigan, T.C. (1994) Failure of short-term CD4-PE40 infusions to reduce viral load in HIV infected individuals. J. Infect. Dis. 170, 1009-1013.
31. - T cells in acute HIV infection in vitro. J. Immunol. 150, 5202-5208.
32. Renneisen, K., Leserman, L., Matthes, E., Schroder, H.C. and Muller, W.E. (1990) Inhibition of expression of human immunodeficiency virus-1 in vitro by antibody-targeted liposomes containing antisense RNA to the env region. J. Biol. Chem. 265, 16337-16342.
33. Rombi, G., Piu, G., Piro, S., Pautasso, M., Garau, G. and Palomba, A. (1992). MAB labelled liposomes as vehicles for AZT: choice of specific monoclonal antibodies for infected cells. VIII Int. Conf. AIDS, Amsterdam, The Netherlands.
34. Strand, V., Lipsky, P.E., Cannon, G.W. et al. (1993) Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis: results of two phase two studies. Arthritis Rheum. 36, 620-630.
35. Thrush, G.R., Lark, L.R., Clinchy, B.C. and Vitetta, E.S. (1996) Immunotoxins: an update. Ann. Rev. Immunol. 14, 49-71.
36. Till, M.A., Zolla-Pazner, S., Gorny, M.K., Patton, J.S., Uhr, J.W. and Vitetta, E.S. (1989) Human immunodeficiency virus-infected T cells and monocytes are killed by monoclonal human anti-gp41 antibodies coupled to ricin A chain. Proc. Natl. Acad. Sci. USA 86, 1987-1991.
37. Tsubota, H., Winkler, G., Meade, H.M., Jakubowski, A., Thomas, D.W. and Letvin, N.L. (1990) CD4-Pseudomonas exotoxin conjugates delay but do not fully inhibit human immunodeficiency virus replication in lymphocytes in vitro. J. Clin. Invest. 86, 1684-1689.
38. Winters, M.A. and Merigan, T.C. (1993) Continuous presence of CD4-PE40 is required for antiviral activity against single passage HIV isolates and infected peripheral blood mononuclear cells. AIDS Res. Hum. Retroviruses 9, 1091-1096.
39. + cells by monoclonal antibodies. Nature 347, 92-95.